AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764

August 20, 2026 7:00 AM

AC Immune SA (NASDAQ: ACIU) announced preliminary results from a Phase 1 first-in-human clinical study of ACI-19764, an oral small ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found